Overview

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Status:
RECRUITING

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if golidocitinib combined with tislelizumab and chemotherapy works in advanced NSCLC with PD-L11%. The main question it aims to answer is: Does the combination of golidocitinib with tislelizumab and chemotherapy can prolong the progression-free survival of patients with advanced NSCLC? Participants will Take tislelizumab and chemotherapy for 2 cycles; and then take tislelizumab and golidocitinib for 2 cycles; after cycle 5, patients receive tislelizumab and chemotherapy until the patients were intolerant or the disease progressed.

Phase:

PHASE1

Details

Lead Sponsor:

Peking University Cancer Hospital & Institute

Treatments:

Carboplatin
Cisplatin
Paclitaxel
Pemetrexed
tislelizumab